Do We Need Meropenem Treatment Beyond 7 Days in Febrile Neutropenic Patients: A Cost-Effectiveness Analysis
Notably, even though the clinical outcomes of STT were not statistically different from those of LTT, the cost of the STT group were statistically significantly lower than that of the LTT group. The early discontinuation of empirical meropenem treatment may offer financial advantages to healthcare systems.
Authors
- Leyla Yumrukaya (ORCID: https://orcid.org/0000-0002-3382-2794)
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Selen Yeğenoğlu (ORCID: https://orcid.org/0000-0002-5217-8797)
- Ahmet Çağkan İnkaya (ORCID: https://orcid.org/0000-0001-7943-8715)
- Murat Akova (ORCID: https://orcid.org/0000-0002-6904-9473)
- Gökhan Metan (ORCID: https://orcid.org/0000-0002-2676-4557)
- Arnold Hagens (ORCID: https://orcid.org/0000-0002-9087-8719)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Universitas Airlangga (ID)
- Hacettepe University (TR)
- Padjadjaran University (ID)
Publication Details
- Journal
- Antibiotics
- Published
- 2025-06-27
- DOI
- https://doi.org/10.3390/antibiotics14070653
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00